---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-017473"
form_type: "8-K"
ticker: "APVO"
cik: "0001671584"
company_name: "Aptevo Therapeutics Inc."
filed_at: "2025-02-11T23:59:59+00:00"
generated_at: "2026-05-26T23:24:35.898268+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "medium"
source: SEC EDGAR
---

# Aptevo Therapeutics provides pipeline update via investor presentation

## Summary
- Presentation highlights clinical candidates mipletamig and ALG.APV-527.
- Preclinical candidates APVO711, APVO603, APVO442 are also detailed.
- No new clinical data, trial results, or financial guidance provided.
- Presentation dated February 11, 2025, furnished under Regulation FD.

## SEC filing metadata
- accession: 0000950170-25-017473
- form_type: 8-K
- ticker: APVO
- cik: 0001671584
- company_name: Aptevo Therapeutics Inc.
- filed_at: 2025-02-11T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: medium
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671584/000095017025017473/0000950170-25-017473-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671584/000095017025017473/apvo-20250211.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-017473
- JSON: https://secwatch.observer/filing/0000950170-25-017473.json
- Plain text: https://secwatch.observer/filing/0000950170-25-017473.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.